



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 MADRID

Granada, 27 October 2015

RELEVANT FACT NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by companies in expansion integrated in the MAB, we hereby puts in knowledge the following information about Neuron Bio, S.A. (hereinafter "NEURON" or "Company").

Today has been approved the Information Document for Admission (DIIM) of Neol Biosolutions, S.A.. Neol Bio starts listing on the MAB next Thursday 29 October at twelve o'clock in the morning for a prize of €1.8 per share.

Press release is enclosed.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Neol Bio to start trading on the MAB next 29 October

Next Thursday 29 October, Neol Bio starts listing on the MAB, once all its conditions are met. The Information Document for Admission (DIIM) on the company that reports data related to the company, its activities and business is already available on the new corporative web www.neolbio.com/accionistas and on the MAB website www.bolsasymercados.es.

Hundred percent of Neol Bio shares will be traded on the Spanish Alternative Equity Market after the free distribution of 25% capital among the NEURON BIO shareholders and after the capital increase among qualified investors amounting €1.55 million. Neol Bio shares will be contracted in continuous trading.

It has been proposed €1.8 per share as reference price, which is the same set to the free distribution and the capital increase.

According to its president, Jose Manuel Arrojo, *“Neol Bio’s listing on the MAB provides us channels for funding in order to guarantee the growth of the company in its current new development phase, due to visibility granted by this market and transparency and rigor requested. The sectors in which we operate, the olechemical, Omega-3 DHA and bioenergy ones and our technologies will allow us, in addition to the appropriate funding, to multiply several times size and value of Neol Bio.*

Javier Velasco, CEO of Neol Bio states, *“The MAB will help to position Neol Bio as a European biotech company with a leading role in the production of high value-added oleochemicals, using pioneering new technology based on microorganisms (yeasts and microalgae) to complete the development of its products and industrial exploitation, where appropriate framed in the platforms MicroBiOil 3.0® y Omega-3 DHA”.*



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

For further information

Malena Valdivieso
mvaldivieso@neuronbio.com
Tel.: +34 958 750 598

Note for editors:

About Neol Bio

Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

Due to the use of advanced molecular biology techniques, bioprocess engineering and industrial microbiology, Neol achieves economically viable bioprocesses, thus reducing the use of chemical contaminants and assessing agricultural and industrial waste.

Neol has facilities, laboratories and cutting-edge equipment in the biotechnology field, as well as an own pilot plant for demonstration of the processes it develops.

Neol has a team of over 30 high qualified researchers, such as microbiologists, molecular biologists, experts in analytical chemistry and bioprocesses engineers with renowned prestige in the sector, who participate actively in numerous scientific projects.

Its headquarters and main facilities are located in the Granada Bio Science & Technology Park.